Financials data is unavailable for this security.
Cash flow in USDView more
In 2024, cash reserves at PharmaCyte Biotech Inc fell by 17.86m. In addition, the company used more cash to support its operations than it earned, posting a cash flow loss of 2.15m. In addition the company used 5.00m on investing activities and also paid 10.71m in financing cash flows.
Cash flow per share | 0.527 |
---|---|
Price/Cash flow per share | 2.90 |
Book value per share | 6.87 |
---|---|
Tangible book value per share | 6.67 |
More ▼
Balance sheet in USDView more
Current ratio | 4.40 |
---|---|
Quick ratio | -- |
Total debt/total equity | 0.00 |
---|---|
Total debt/total capital | 0.00 |
More ▼